TMS Treatment of Social Cognition Skills in Mild Cognitive Impairment

This is a prospective, double-binding, cross-sectional, randomized, sham-controlled, and single-center project aimed to investigate the effect of rTMS treatment of social cognition abilities in MCI subjects at 2 and 4 weeks, and after 8 weeks from baseline.

All patients will be recruited at Clinical Neuroscience Institute, Department of Neurology, Regional Civic Hospital, Lugan; Department of Geriatric Italian Hospital Viganello; and Department of Geriatric, Beata Vergine Hospital Mendrisio; Southern Switzerland, Switzerland.

Primary objective:

• To investigate whether the application of high-frequency rTMS, for 2 or 4 weeks, to the RPTJ and MPFC resulted in social cognitive improvements.

Secondary objectives:

• To verify whether the social cognition benefits previously recorded might persist after 8 weeks the end of the stimulation, with a major benefit with a longer rTMS application (4 weeks).
• To investigate whether the application of high-frequency rTMS, at 2 weeks or 4 weeks, to the RPTJ and MPFC contributes to improve cognitive functions as well as neuropsychiatric (depression) and functional aspects.
• To verify whether the cognitive functions, neuropsychiatric aspect, and functional benefits previously recorded persist after the end of the rTMS stimulation.

Primary analysis: To investigate the behavioral effects induced by the rTMS protocol after 2 and 4 weeks of daily stimulation on social cognition skills, executive/attentive functions, neuropsychiatric and functional aspects will be used a mixed-model ANOVA, considering the group as a between-subjects factor, and time as a within-subject factor.

Secondary Analyses: To investigate the direct or mediated rTMS effect on social cognition skills, a multivariate linear regression analysis will be done for each social cognition measure (ToM, empathy, social perception, social behavior) changes after rTMS treatment at 2 and 4 weeks as the dependent factor, separately, and appropriate screening/baseline dependent variables and rTMS groups as independent factors.

The evaluation and treatment of social cognition alterations in subjects with MCI can be useful for two main aspects: first, the mild cognitive and behavior impairment of these subjects favor a better answer at the treatment, both at the behavioral level and in terms of brain structural and functional response; second, treatment of these abilities in MCI population might retard the conversion to dementia. More importantly, the detection of predominant social cognition alteration in early phases of cognitive decline might be potentially helpful to differentiate individuals who will develop frontotemporal dementia. Therefore, it is important to investigate and define a treatment protocol to limit social cognition disturbances in MCI.

Inclusion criteria

• Subjects aged 50 to 85 years old, inclusive, at the time of informed consent;
• Must have at least 5 years of education or work experience to exclude mental deficits other than MCI;
• Must meet Petersen's criteria for mild cognitive impairment, and must have:
• Clinical dementia rating global score of 0.5;
• Mini-Mental State Examination score between 24 and 30;
• Must have a score ≥ 26.5 at Token test to ensure that subjects have the ability to understand the instructions and procedures;
• Must have a score < 29 at Beck Depression Inventory to exclude major depression that could compromise the patient's ability to engage in the study;
• Apart from a clinical diagnosis of MCI, the subject must be in good health;
• Must be on stable dose of antidepressant (if applicable) for at least 2 months prior to the enrolment.

Exclusion criteria

• Any uncontrolled medical or neurological/neurodegenerative condition (other than MCI);
• Clinical significant unstable psychiatric illness requiring treatment with neuroleptic;
• Transient ischemic attack, stroke, or any unexplained loss of consciousness or severe ongoing stressor within 1 year prior to screening;
• History of seizure within10 years prior to screening;
• Recent history of alcohol or substance abuse or use of cannabinoids;
• Any other medical conditions that are not stable or controlled, or could affect the subject's safety or interfere with the study assessments and treatment;
• Contraindication to having TMS treatment;
• Inability to understand the purpose of the study or to comply with study requirements.